Sugi Predict

Sugi Predict / Compounds / SCHEMBL257626

SCHEMBL257626

SCHEMBL257626

OB(O)c1ccc(Oc2cc(F)cc(F)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 5/20 0.59
▸ CA1 P00915 4/20 0.59
▸ ENPP2 Q13822 4/20 0.47
▸ VEGFA P15692 2/20 0.40
▸ MGLL Q99685 1/20 0.38
▸ TSHR P16473 1/20 0.37
▸ ORAI1 Q96D31 1/20 0.37
▸ ORAI2 Q96SN7 1/20 0.37
▸ ORAI3 Q9BRQ5 1/20 0.37
▸ TRPV6 Q9H1D0 1/20 0.37
▸ LPL P06858 1/20 0.37
▸ LIPG Q9Y5X9 1/20 0.37
▸ TTR P02766 1/20 0.36
▸ TUBB4A P04350 1/20 0.36
▸ TUBB P07437 1/20 0.36
▸ TUBA3C P0DPH7 1/20 0.36
▸ TUBA1B P68363 1/20 0.36
▸ TUBA4A P68366 1/20 0.36
▸ TUBB4B P68371 1/20 0.36
▸ TUBB3 Q13509 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257871 0.85 CA2 (0.65) CA2CA1ENPP2MGLLTSHR
SCHEMBL257921 0.85 CA1 (0.66) CA2CA1ENPP2MGLL
SCHEMBL8655522 0.85 CA1 (0.46) CA2CA1ENPP2VEGFAORAI1
SCHEMBL6001606 0.82 CA2 (0.81) CA2CA1ENPP2MGLLTSHR
SCHEMBL10715281 0.82 VEGFA (0.46) CA1VEGFATSHR
SCHEMBL257624 0.82 CA2 (0.57) CA2CA1ENPP2MGLLTSHR
SCHEMBL12420200 0.80 CA1 (0.50) CA2CA1ENPP2VEGFA
SCHEMBL257819 0.78 CA2 (0.57) CA2CA1ENPP2MGLLTSHR
SCHEMBL4046325 0.77 ESR1 (0.64) CA1VEGFA
SCHEMBL257635 0.76 CA2 (0.59) CA2CA1ENPP2TSHRLPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912979-B1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
US-20250197402-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-06-19 — — US disclosed
CN-113149983-B Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2024-03-29 — — CN disclosed
US-20230151012-A1 TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2023-05-18 — — US disclosed
EP-4112618-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2023-01-04 — — EP disclosed
US-20220213092-A1 BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS ABBVIE INC (US) 2022-07-07 — — US disclosed
WO-2022132997-A1 BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS ABBVIE INC. (US) 2022-06-23 — — WO disclosed
EP-3912979-A1 TYROSINE KINASE INHIBITORS Principia Biopharma Inc. (US) 2021-11-24 — — EP disclosed
CN-113149983-A Tyrosine kinase inhibitors 普林斯匹亚生物制药公司 2021-07-23 — — CN disclosed
US-20210171526-A1 Tyrosine Kinase Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-06-10 — — US disclosed
US-20110230440-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE ADAMS JULIAN 2011-09-22 — — US disclosed
US-20110230440-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE ADAMS JULIAN 2011-09-22 — — US disclosed
US-20110224171-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. 2011-09-15 — — US disclosed
US-20110224171-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. 2011-09-15 — — US disclosed
EP-2073816-B1 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS INC (US) 2011-09-14 — — EP disclosed
US-7947663-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2011-05-24 — — US disclosed
US-7947663-B2 Inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2011-05-24 — — US disclosed
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. (US) 2009-04-16 — — US disclosed
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY DISCOVERY, INC. (US) 2009-04-16 — — US disclosed
WO-2008063300-A2 BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224171-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CA2 1331/4885CA1 908/4885ENPP2 36/4885
US-20220213092-A1 BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS BTK, LYN, ABL1 CA2 4115/4885CA1 4784/4885ENPP2 4009/4885
US-20210171526-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK CA2 3685/4885CA1 4614/4885ENPP2 381/4885
US-20090099131-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CA2 1331/4885CA1 908/4885ENPP2 36/4885
US-20110230440-A1 INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, ASAH1 CA2 1331/4885CA1 908/4885ENPP2 36/4885
US-20230151012-A1 TYROSINE KINASE INHIBITORS BTK, LYN, SYK CA2 3685/4885CA1 4614/4885ENPP2 381/4885
US-20250197402-A1 Tyrosine Kinase Inhibitors BTK, LYN, SYK CA2 3685/4885CA1 4614/4885ENPP2 381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.